April 4th, 2020


Volume 52
Number 2
   
 Editorial
73
Lawrence D. Devoe, M.D.


 Original Article
75
Joanne Robinson, R.N., M.S.P.H., Vicki Seltzer, M.D., Loretta Lawrence, M.D., George Autz, M.D., Karen Kostroff, M.D., Lora Weiselberg, M.D., and Maria Colagiacomo
Health care employees were noncompliant with mammography screening recommendations, and an employee inreach program substantially improved compliance.


 Proceedings of the XVIIIth World Congress of the International Society for the Study of Vulvovaginal Disease, Queenstown, New Zealand, February 20-24, 2006
78
Christiane Schausberger, M.D., Lucia Six, M.D., Reinhard Horvat, M.D., and Elmar A. Joura, M.D.
A case of recurrent HPV-related disease of the lower genital tract and microinvasive vulvar cancer was followed by groin metastasis.


81
Gayle Fischer, M.B.B.S., F.A.C.D.
Genital fixed drug eruption should be considered in the presence of any acute or recurrent vulvitis.


87
Ruth Murphy, MMedSci (Med Ed), PhD, FRCP
In training medical practitioners interested in vulvovaginal diseases, there was a bias towards miniclinical evaluation exercises and direct observation as methods of assessment.


93
R. Stuart Fowler, M.D., F-ACOG, F-ISSVD
Phase-contrast microscopy of wet preparations from symptomatic women showed 2 patterns of altered vaginal flora that are not recognized in the current classification system of vaginitis.


100
Isabel C. Chulvis do Val, Ph.D., Gutemberg L. Almeida Filho, Ph.D., Adriana Corrāea, Ph.D., and Nereu Neto, M.D.
Chronic hidradenitis suppurativa of the genital and perianal regions may be associated with cancer.


103
Gayle Harris, M.D., Benson Horowitz, M.D., and Adam Borgida, M.D.
Gabapentin appears to be very effective in the treatment of generalized vulvodynia, unprovoked, and has a very low side effect profile.


107
Franco Mascherpa, M.D., Fabrizio Bogliatto, M.D., Peter J. Lynch, M.D., Leonardo Micheletti, M.D., and Chiara Benedetto, M.D., Ph.D.
Vulvodynia can be considered a somatoform disorder affecting the vulva, and any patient with it should always be investigated from a sexual and psychodynamic point of view.


 Letter to the Editors
140
Daniel A. Goldstein, M.D., David F. Kowalczyk, V.M.D., Ph.D., John L. Vicini, Ph.D., Fran C. Buonomo, Ph.D., and Donna R. Farmer, Ph.D.


141
  


 Supplement
 The Role of Aldosterone in Progression of Hypertension: How It Affects Women in Menopause
143


147
Sandra J. Lewis, M.D.
Since the prevalence of heart disease and hypertension is increased in postmenopausal women, gynecologists need to be aware of these risks and recognize cardiovascular problems in their patients.


153
Bertram Pitt, M.D.
This review of the role of aldosterone in the pathophysiology of hypertension and heart disease supports the advantages of blocking the mineralocorticoid receptor with antialdosterone agents.


159
David F. Archer, M.D.
The combination of drospirenone and 17?-estradiol provides effective and safe relief from menopausal symptoms and has a beneficial effect on blood pressure and weight gain.


165
Mary Jane Minkin, M.D.
Antialdosterone-containing hormonal therapy (HT) offers postmenopausal women advantages beyond simply the relief of menopausal symptoms; drospirenone/estradiol therapy has the theoretical advantage of modulating postmenopausal cardiovascular target organ complications and represents an attractive alternative to other forms of HT.


169


 

The opinions and statements in this journal are those of the authors and are not attributable to the sponsor, publisher, editors or editorial board of JRM. Product dosages, indications and methods of use referred to in the papers and discussions reflect the authors' clinical experience or are derived from other professional sources.